Complementary advances in molecular imaging and targeted therapeutics for urothelial cancer are providing new opportunities for more effective personalized treatment. Tumor-specific positron emission ...

En bloc resection of bladder tumor has recently emerged as an alternative to TURBT aiming to improve surgical quality and pathological assessment.

Circulating tumor DNA (ctDNA) is an emerging technology that is rapidly transforming the management of patients with cancer -- not only in hematologic malignancies, but increasingly also in solid ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer Circulating tumor DNA (ctDNA) is increasingly being used to ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer. Increases in circulating tumor DNA fraction ...

FDA fast track enables increased FDA-company interactions and potential rolling BLA submission to accelerate development for serious diseases with unmet need. AKY-1189 uses a miniprotein ...